MARKET

MNKD

MNKD

Mannkind
NASDAQ
4.590
0.000
0.00%
After Hours: 4.600 +0.01 +0.22% 17:37 05/17 EDT
OPEN
4.600
PREV CLOSE
4.590
HIGH
4.615
LOW
4.515
VOLUME
2.12M
TURNOVER
0
52 WEEK HIGH
5.75
52 WEEK LOW
3.170
MARKET CAP
1.25B
P/E (TTM)
196.15
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MNKD last week (0513-0517)?
Weekly Report · 8h ago
MannKind Outperforms As Tyvaso DPI Captures Market Share
Seeking Alpha · 5d ago
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
NASDAQ · 05/13 16:00
Weekly Report: what happened at MNKD last week (0506-0510)?
Weekly Report · 05/13 10:36
Oppenheimer Remains a Buy on MannKind (MNKD)
TipRanks · 05/10 11:57
MannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical Developments
TipRanks · 05/10 05:28
MannKind Price Target Maintained With a $6.50/Share by Cantor Fitzgerald
Dow Jones · 05/09 15:06
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target
Benzinga · 05/09 14:56
More
About MNKD
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Webull offers MannKind Corp stock information, including NASDAQ: MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.